Browse > Article
http://dx.doi.org/10.5483/BMBRep.2014.47.4.157

Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model  

Kwon, Sanghoon (Center for Medical Science Research, College of Medicine, Hallym University)
Kim, Young-Eun (Department of Biochemistry, College of Natural Sciences, Chungbuk National University)
Park, Jeong-A (Department of Biochemistry, College of Natural Sciences, Chungbuk National University)
Kim, Doo-Sik (Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University)
Kwon, Hyung-Joo (Center for Medical Science Research, College of Medicine, Hallym University)
Lee, Younghee (Department of Biochemistry, College of Natural Sciences, Chungbuk National University)
Publication Information
BMB Reports / v.47, no.4, 2014 , pp. 215-220 More about this Journal
Abstract
Molecular-targeted therapy has gained attention because of its high efficacy and weak side effects. Previously, we confirmed that transmembrane 4 superfamily member 5 protein (TM4SF5) can serve as a molecular target to prevent or treat hepatocellular carcinoma (HCC). We recently extended the application of the peptide vaccine, composed of CpG-DNA, liposome complex, and TM4SF5 peptide, to prevent colon cancer in a mouse model. Here, we first implanted mice with mouse colon cancer cells and then checked therapeutic effects of the vaccine against tumor growth. Immunization with the peptide vaccine resulted in robust production of TM4SF5-specific antibodies, alleviated tumor growth, and reduced survival rate of the tumor-bearing mice. We also found that serum levels of VEGF were markedly reduced in the mice immunized with the peptide vaccine. Therefore, we suggest that the TM4SF5-specific peptide vaccine has a therapeutic effect against colon cancer in a mouse model.
Keywords
Animal model; Colon cancer; Peptide vaccine; Therapeutics; TM4SF5;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Abbas, A., Lichtman, A. and Pillai, S. (2010) Cellular and molecular immunology, 6th ed., pp. 351-373, Saunders, Elsevier, Philadelphia, U.S.A.
2 Aly, H. A. (2012) Cancer therapy and vaccination. J. Immunol. Methods 382, 1-23.   DOI   ScienceOn
3 Klinman, D. M., Currie, D., Gursel I and Verthelyi D. (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201-216.   DOI   ScienceOn
4 Lee, K. W., Jung, J., Lee, Y., Kim, T. Y., Choi, S. Y., Park, J., Kim, D. S. and Kwon, H. J. (2006) Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol. Immunol. 43, 2107-2118.   DOI   ScienceOn
5 Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. and Krieg, A. M. (1998) CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876.
6 Carson, D. A. and Raz, E. (1997) Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med. 186, 1621-1622.   DOI
7 Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. and Harding, C. V. (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623-1631.   DOI   ScienceOn
8 Kim, D., Kwon, S., Ahn, C. S., Lee, Y., Choi, S. Y., Park, J., Kwon, H. Y. and Kwon, H. J. (2011) Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep. 44, 758-763.   과학기술학회마을   DOI   ScienceOn
9 Kim, D., Kwon, S., Rhee, J. W., Kim, K. D., Kim, Y. E., Park, C. S., Choi, M. J., Suh, J. G., Kim, D. S., Lee, Y. and Kwon, H. J. (2011) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol. 12, 29.   DOI   ScienceOn
10 Kim, D., Kwon, H. J. and Lee, Y. (2011) Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep. 44, 607-612.   과학기술학회마을   DOI   ScienceOn
11 Lee, Y. and Kwon, H. J. (2012) Production of epitope-specific antibodies using peptide-CpG-ODN-liposome complex without carriers and their application as a cancer vaccine in mice. Oncoimmunology. 1, 1215-1217.   DOI
12 Llovet, J. M. and Bruix, J. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327.   DOI   ScienceOn
13 Lee, S. A., Ryu, H. W., Kim, Y. M., Choi, S., Lee, M. J., Kwak, T. K., Kim, H. J., Cho, M., Park, K. H. and Lee, J. W. (2009) Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 49, 1316-1325.   DOI   ScienceOn
14 Tanaka, S. and Arii, S. (2011) Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J. Gastroenterol. 46, 289-296.   DOI
15 Muller-Pillasch, F., Wallrapp, C., Lacher, U., Friess, H., Buchler, M., Adler, G. and Gress, T. M. (1998) Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene 208, 25-30.   DOI   ScienceOn
16 Lee, S. A., Lee, S. Y., Cho, I. H., Oh, M. A., Kang, E. S., Kim, Y. B., Seo, W. D., Choi, S., Nam, J. O., Tamamori- Adachi, M., Kitajima, S., Ye, S. K., Kim, S., Hwang, Y. J., Kim, I. S., Park, K. H. and Lee, J. W. (2008) Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J. Clin. Invest. 118, 1354-1366.   DOI   ScienceOn
17 Kwon, S., Kim, D., Park, B. K., Cho, S., Kim, K. D., Kim, Y. E., Park, C. S., Ahn, H. J., Seo, J. N., Choi, K. C., Kim, D. S., Lee, Y. and Kwon, H. J. (2012) Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One. 7, e33121.   DOI   ScienceOn
18 Kwon, S., Kim, D., Park, B. K., Wu, G., Park, M. C., Ha, Y. W., Kwon, H. J. and Lee, Y. (2013) Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncol. Rep. 29, 735-740.   DOI
19 Kwon, S., Kim, Y. E., Kim, D., Park, B. K., Wu, G., Kim, T. H., Choi, S. H., Kim, D. S., Kwon, H. J. and Lee, Y. (2013) Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model. Biochem. Biophys. Res. Commun. 435, 134-139.   DOI   ScienceOn
20 Mercurio, A. M., Lipscomb, E. A. and Bachelder, R. E. (2005) Non-angiogenic functions of VEGF in breast cancer. J. Mammary Gland Biol. Neoplasia. 10, 283-290.   DOI
21 Schreiber, T. H., Raez, L., Rosenblatt, J. D. and Podack, E. R. (2010) Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin. Immunol. 22, 105-112.   DOI   ScienceOn
22 Choi, K. S., Bae, M. K., Jeong, J. W., Moon, H. E. and Kim, K. W. (2003) Hypoxia-induced angiogenesis during carcinogenesis. J. Biochem. Mol. Biol. 36, 120-127.   DOI   ScienceOn
23 Choi, S., Lee, S. A., Kwak, T. K., Kim, H. J., Lee, M. J., Ye, S. K., Kim, S. H., Kim, S. and Lee, J. W. (2009) Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood 113, 1845-1855.   DOI   ScienceOn
24 Yoshiji, H., Kuriyama, S., Ways, D. K., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Tsujinoue, H., Nakatani, T., Shibuya, M. and Fukui, H. (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59, 4413-4418.
25 Kim, N. H., Park, H. J., Oh, M. K., and Kim, I. S. (2013) Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep. 46, 59-64.   과학기술학회마을   DOI   ScienceOn
26 Zhou, C., Shen, Q., Xue, J., Ji, C., and Chen, J. (2013) Overexpression of TTRAP inhibits cell growth and induces apoptosis in osteosarcoma cells. BMB Rep. 46, 113-118.   과학기술학회마을   DOI   ScienceOn
27 Montomoli, E., Piccirella, S., Khadang, B., Mennitto, E., Camerini, R. and De Rosa, A. (2011) Current adjuvants and new perspectives in vaccine formulation. Expert. Rev. Vaccines 10, 1053-1061.   DOI
28 Bode, C., Zhao, G., Steinhagen, F., Kinjo, T. and Klinman, D. M. (2011) CpG DNA as a vaccine adjuvant. Expert. Rev. Vaccines 10, 499-511.   DOI   ScienceOn
29 Yoshiji, H., Kuriyama, S., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H. and Fukui, H. (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 7, 1073-1078.
30 Krieg, A. M. (2002) CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760.   DOI   ScienceOn